The shot, mFlusiva, was given a traditional approval ‌for adults aged 50 to 64, and an accelerated approval for those 65 years and older. The company also submitted separate late-stage data showing the vaccine generated stronger antibody responses than ⁠Sanofi's high-dose flu vaccine in adults 65 and older. MFlusiva would compete with flu vaccines from Sanofi, GSK, CSL Seqirus, and AstraZeneca. Advertisement AdvertisementAdvertisement AdvertisementJefferies analysts had forecast $750 ​million in U.S. sales of Moderna's flu shot and combination ​COVID-flu vaccine by 2030. Former FDA Commissioner Marty Makary and former vaccine chief Vinay Prasad were forced to resign earlier ​this year amid controversies over vaccine ‌and rare-disease drug reviews, including Moderna's flu vaccine application.